Eli Lilly has become the first drugmaker to gain approval in China for a GLP-1 weight loss pill, orforglipron, leapfrogging rival Novo Nordisk in the world's second-largest pharmaceutical market. The pill targets patients reluctant to use injections, with China's obesity rate projected to exceed 65%
A practical guide for managers on using HumanBenchmark.now typing and processing-speed tests at work, covering device effects, accessibility, practice bias, fairness, and strict boundaries against using casual scores for hiring or discipline.
